A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models

Glioblastoma (GBM) is the least treatable type of brain tumor, afflicting over 15,000 people per year in the United States. Patients have a median survival of 16 months, and over 95% die within 5 years. The chemokine receptor ACKR3 is selectively expressed on both GBM cells and tumor-associated bloo...

Descripción completa

Detalles Bibliográficos
Autores principales: Salazar, Nicole, Carlson, Jeffrey C., Huang, Kexin, Zheng, Yayue, Oderup, Cecilia, Gross, Julia, Jang, Andrew D., Burke, Thomas M., Lewén, Susanna, Scholz, Alexander, Huang, Serina, Nease, Leona, Kosek, Jon, Mittelbronn, Michel, Butcher, Eugene C., Tu, Hua, Zabel, Brian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993942/
https://www.ncbi.nlm.nih.gov/pubmed/29606504
http://dx.doi.org/10.1016/j.ymthe.2018.02.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993942/
https://www.ncbi.nlm.nih.gov/pubmed/29606504
http://dx.doi.org/10.1016/j.ymthe.2018.02.030

Ejemplares similares